Brief: Syndax Pharma Reports First Quarter 2023 Financial Results

Syndax Pharmaceuticals

08/05/2023 23:28

May 8 (Reuters) - Syndax Pharmaceuticals Inc  SNDX.O :
    * SYNDAX PHARMACEUTICALS REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE
    * TOPLINE DATA FROM PIVOTAL AGAVE-201 TRIAL OF AXATILIMAB IN
CGVHD
ON TRACK FOR MID-2023
    * TWO U.S. REGISTRATIONAL FILINGS EXPECTED BY END OF 2023
    * TOPLINE DATA FROM PIVOTAL AUGMENT-101 TRIAL OF REVUMENIB
IN
KMT2AR ACUTE LEUKEMIA ON TRACK FOR Q3 OF 2023
    * QTRLY LOSS PER SHARE $0.59
    * Q1 EARNINGS PER SHARE VIEW $-0.60 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nPn8hQCsPa 
Further company coverage:  SNDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))